Pregabalin Capsule
Product Images NDC 72162-1547

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621547)

Pregabalin Capsules, USP 225 mg oral capsules label showing repackaging by Bryant Ranch Prepack, Inc., Burbank, CA, and manufacturing by ScieGen Pharmaceuticals, Inc. The label includes NDC 72162-1547, quantity of 90 capsules, a barcode, and storage instructions to keep at 20° to 25° C with allowed excursions.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, illustrating patient response across different dosing levels.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows two curves indicating the response rates over a range of pain improvement percentages from 0 to 100%.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to placebo. The graph shows higher improvement percentages with increasing doses of Pregabalin.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph illustrates a higher percentage of patients improved with Pregabalin doses compared to placebo across various improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved against percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph illustrates higher improvement percentages for Pregabalin groups compared to placebo.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different dosing regimens of Pregabalin versus placebo in two clinical studies, Study E1 and Study E3. The x-axis shows dosage groups including placebo and various daily doses, and the y-axis shows responder rates from 0% to 60%. Statistically significant differences versus placebo are noted.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline versus dose (mg/day) for Pregabalin. Data points represent four studies with different dosing schedules (E1 BID, E2 TID, E3 BID, E3 TID). Significant p-values are noted, showing increased seizure reduction with higher doses up to 600 mg/day. Placebo dose is zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 800 mg, 450 mg, 300 mg daily doses, and placebo. Different line styles represent each group, with improvement rates declining as pain improvement increases.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The solid line represents Pregabalin and the dashed line represents placebo, showing higher survival without LTR in the Pregabalin group throughout the study period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over different percentages of improvement from baseline to week 12, labeled 'BOCF.' The graph has two lines: a solid line representing Pregabalin and a dashed line representing Placebo, showing Pregabalin consistently higher. The x-axis is labeled 'Percent Improved from Baseline to Week 12 BOCF' ranging roughly from 0 to 100 percent, and the y-axis is labeled 'Percent of Subjects Improved' ranging 0 to 100 percent.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing percentage of subjects improved between Pregabalin and Placebo groups from baseline to Week 16. The x-axis shows percent improvement ranging from 0 to 100, and the y-axis shows percent of subjects improved. Two lines represent Pregabalin (solid line) and Placebo (dashed line), with the Pregabalin line generally higher, indicating a greater percentage of subjects improved at different improvement thresholds.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) using age, weight, serum creatinine, and a factor for female patients. The formula is shown as an equation with variables and multiplication components.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin showing its molecular framework, including an amino group, carboxylic acid group, and branching carbon chains as depicted in the diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.